{"id":"ivermectin-colchicine","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances (nausea, diarrhea)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Colchicine-related diarrhea and abdominal pain"},{"rate":null,"effect":"Myalgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ivermectin binds to glutamate-gated chloride channels in parasites, causing paralysis and death, while also exhibiting immunomodulatory effects that suppress pro-inflammatory cytokines. Colchicine inhibits microtubule polymerization, reducing neutrophil migration and inflammatory mediator release. Together, they target both parasitic infection and excessive inflammatory responses.","oneSentence":"This combination uses ivermectin's antiparasitic and anti-inflammatory properties alongside colchicine's anti-inflammatory effects to reduce inflammation and parasitic burden.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:50:41.781Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parasitic infections with inflammatory complications"},{"name":"COVID-19 (investigational use in some regions)"}]},"trialDetails":[{"nctId":"NCT05930002","phase":"NA","title":"Role of Ivermectin and Colchicine in Treatment of COVID-19: Randomized Controlled Clinical Trial","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2021-07-21","conditions":"COVID-19","enrollment":120},{"nctId":"NCT05246072","phase":"PHASE4","title":"Effect of Combined Use of Ivermectin and Colchicine in COVID-19 Patients","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2021-11-01","conditions":"COVID-19","enrollment":135}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":25,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Ivermectin + colchicine","genericName":"Ivermectin + colchicine","companyName":"Ain Shams University","companyId":"ain-shams-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses ivermectin's antiparasitic and anti-inflammatory properties alongside colchicine's anti-inflammatory effects to reduce inflammation and parasitic burden. Used for Parasitic infections with inflammatory complications, COVID-19 (investigational use in some regions).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}